Drug Discovery Opinion

The main symptoms of Parkinson’s disease are tremor, rigidity and involuntary movement, caused by loss of dopaminergic neurons in the brain. Leucine-rich repeat protein kinase-2 (LRRK2) is mutated in a significant number of Parkinson’s disease cases, both familial and sporadic late-onset. A common mutation in which a glycine residue in the active site is altered to serine enhances catalytic activity of the kinase, suggesting that LRRK2 inhibitors might be useful for the treatment of Parkinson’s disease, although it is not entirely clear why enhanced LRRK2 activity causes loss of dopamine-producing neurons. Scientists led by a team at the Johns Hopkins University School of Medicine have now shown that inhibitors of the G2019S variant of LRRK2 can protect the nerve cells of mice genetically modified to produce the mutated kinase. Three weeks twice daily injections of GW5074 provided almost complete protection against loss of dopaminergic neurons compared with placebo treatment.

Although GW5074 is not an especially potent inhibitor of wild type or G2019S LRRK2 (IC₅₀ 0.2µM – 1.0µM depending on substrate) and is not selective (IC₅₀ vs cRaf ca 10nM), the study, which is published in Nature Medicine, provides encouragement that a more potent and selective inhibitor could lead to a new disease-modifying treatment for Parkinson’s disease. The John Hopkins team are collaborating with researchers at Southern Methodist University to design more selective inhibitors and many other groups in both industry and academia are engaged in the search for potent and selective LRRK2 inhibitors.

Related posts:

1. E3 Ubiquitin Ligase CHIP Regulates LRRK2 Stability Although mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) have been linked to both familial and sporadic cases...
2. Role for c-Abl in Parkinson’s Disease The majority of Parkinson’s disease (PD) cases have no known cause, but have been associated with increased oxidative stress and...
3. Statins Protect Mice from Symptoms of Parkinson’s Disease Statins lower cholesterol by inhibiting HMG-CoA reductase, the rate-limiting step in cholesterol biosynthesis, and new indications have continued to emerge...
4. New Brain Delivery Strategy for Parkinson’s Disease The blood-brain barrier (BBB) fulfills an essential role by restricting the entry of potentially neurotoxic chemicals into brain tissue. The...
5. Potent Inhibitor of Insulin Degrading Enzyme Reported A new study from a Mayo Clinic-led research team has identified novel, potent inhibitors of insulin degrading enzyme (IDE). Despite...

Related posts brought to you by Yet Another Related Posts Plugin.

 Email This Post

This entry was posted on Thursday, August 26th, 2010 at 9:07 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.